Literature DB >> 15138213

Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography.

M Kitano1, M Kudo, K Maekawa, Y Suetomi, H Sakamoto, N Fukuta, R Nakaoka, T Kawasaki.   

Abstract

BACKGROUND: Coded phase inversion harmonic ultrasonography, a newly available sonographic technique, enables visualisation of slow flow in minute vessels in a real time fashion with the use of a sonographic contrast agent containing monosaccharide. Our purpose was to employ this novel technique to observe microvessels in pancreatic tumours. SUBJECTS AND METHODS: Sixty five patients with suspicious pancreatic tumours received contrast enhanced coded phase inversion harmonic ultrasonography, contrast enhanced computed tomography, and endosonography. Final diagnoses based on histological findings were pancreatic ductal carcinomas in 49 patients, inflammatory pseudotumours with chronic pancreatitis in seven, and endocrine tumours in nine. For contrast enhanced coded harmonic ultrasonography, Levovist, a contrast agent, was injected intravenously as a bolus. When the first microbubble signal appeared in the pancreas, images of the ideal scanning plane were displayed in a real time continuous fashion (vessel images). Subsequently, interval delay scanning (perfusion images) was taken to demonstrate parenchymal flow. Tumour vascularity was evaluated by using the two types of imaging. Sensitivities for depicting pancreatic tumours were compared between three examinations.
RESULTS: Contrast enhanced ultrasonography demonstrated tumour vessels in 67% of pancreatic ductal carcinomas, although most were relatively hypovascular compared with the surrounding pancreatic tissue. The vascular patterns of tumours obtained by contrast enhanced ultrasonography were closely correlated with those obtained by contrast enhanced computed tomography. Values for sensitivity in depicting pancreatic tumours of 2 cm or less in size were 68% for contrast enhanced computed tomography, 95% for endosonography, and 95% for contrast enhanced ultrasonography.
CONCLUSION: Contrast enhanced coded phase inversion harmonic ultrasonography successfully visualised fine vessels in pancreatic tumours and may play a pivotal role in the depiction and differential diagnosis of pancreatic tumours.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138213      PMCID: PMC1774066          DOI: 10.1136/gut.2003.029934

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT.

Authors:  H Ding; M Kudo; H Onda; Y Suetomi; Y Minami; H Chung; T Kawasaki; K Maekawa
Journal:  Radiology       Date:  2001-12       Impact factor: 11.105

2.  Transcatheter arterial chemoembolization of hepatocellular carcinoma: usefulness of coded phase-inversion harmonic sonography.

Authors:  Yasunori Minami; Masatoshi Kudo; Toshihiko Kawasaki; Masayuki Kitano; Hobyung Chung; Kiyoshi Maekawa; Hitoshi Shiozaki
Journal:  AJR Am J Roentgenol       Date:  2003-03       Impact factor: 3.959

3.  Percutaneous radiofrequency ablation guided by contrast-enhanced harmonic sonography with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome.

Authors:  Yasunori Minami; Masatoshi Kudo; Toshihiko Kawasaki; Hobyung Chung; Chikara Ogawa; Hitoshi Shiozaki
Journal:  AJR Am J Roentgenol       Date:  2004-05       Impact factor: 3.959

4.  Hepatocellular carcinoma: depiction of tumor parenchymal flow with intermittent harmonic power Doppler US during the early arterial phase in dual-display mode.

Authors:  H Ding; M Kudo; H Onda; Y Suetomi; Y Minami; K Maekawa
Journal:  Radiology       Date:  2001-08       Impact factor: 11.105

5.  Echo-enhanced color- and power-Doppler EUS for the discrimination between focal pancreatitis and pancreatic carcinoma.

Authors:  D Becker; D Strobel; T Bernatik; E G Hahn
Journal:  Gastrointest Endosc       Date:  2001-06       Impact factor: 9.427

6.  Inflammatory pancreatic masses: differentiation from ductal carcinomas with contrast-enhanced sonography using carbon dioxide microbubbles.

Authors:  K Koito; T Namieno; T Nagakawa; K Morita
Journal:  AJR Am J Roentgenol       Date:  1997-11       Impact factor: 3.959

7.  Assessment of the vascularization of neuroendocrine tumors by stimulated acoustic emission of SH U 508A ultrasound contrast agent and color or power Doppler sonography.

Authors:  J Ricke; E L Hänninen; H Amthauer; A Lemke; R Felix
Journal:  Invest Radiol       Date:  2000-04       Impact factor: 6.016

8.  Pancreatic-phase versus portal vein-phase helical CT of the pancreas: optimal temporal window for evaluation of pancreatic adenocarcinoma.

Authors:  G W Boland; M E O'Malley; M Saez; C Fernandez-del-Castillo; A L Warshaw; P R Mueller
Journal:  AJR Am J Roentgenol       Date:  1999-03       Impact factor: 3.959

9.  Contrast-enhanced endoscopic ultrasonography with galactose microparticles: SHU508 A (Levovist).

Authors:  M S Bhutani; B J Hoffman; A van Velse; R H Hawes
Journal:  Endoscopy       Date:  1997-09       Impact factor: 10.093

10.  Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography.

Authors:  Yan Ling Wen; Masatoshi Kudo; Rong Qin Zheng; Yasunori Minami; Hobyung Chung; Yoichiro Suetomi; Hirokazu Onda; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi Maekawa
Journal:  AJR Am J Roentgenol       Date:  2003-07       Impact factor: 3.959

View more
  61 in total

1.  Recent developments in diagnosis of pancreatic cancer.

Authors:  Arjun S Takhar; Ponni Palaniappan; Rajpal Dhingsa; Dileep N Lobo
Journal:  BMJ       Date:  2004-09-18

2.  Evaluation of vascular signal in pancreatic ductal carcinoma using contrast enhanced ultrasonography: effect of systemic chemotherapy.

Authors:  A Kobayashi; T Yamaguchi; T Ishihara; H Tadenuma; K Nakamura; H Saisho
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 3.  Clinical significance of vascular assessment by contrast-enhanced harmonic ultrasonography of pancreatic carcinomas.

Authors:  Masayuki Kitano
Journal:  J Gastroenterol       Date:  2005-06       Impact factor: 7.527

Review 4.  Endoscopic ultrasound advances, part 1: diagnosis.

Authors:  Edward Kim; Jennifer J Telford
Journal:  Can J Gastroenterol       Date:  2009-09       Impact factor: 3.522

5.  Diagnostic value of endoscopic ultrasound-guided directional eFLOW in solid pancreatic lesions.

Authors:  Kunal Das; Masatoshi Kudo; Masayuki Kitano; Hiroki Sakamoto; Takamitsu Komaki; Tadayuki Takagi; Kenji Yamao
Journal:  J Med Ultrason (2001)       Date:  2013-01-23       Impact factor: 1.314

Review 6.  Autoimmune pancreatitis: with special reference to a localized variant.

Authors:  Go Kobayashi; Naotaka Fujita; Yutaka Noda; Kei Ito; Jun Horaguchi
Journal:  J Med Ultrason (2001)       Date:  2008-07-04       Impact factor: 1.314

7.  Contrast-enhanced sonography of pancreatic ductal carcinoma using agent detection imaging.

Authors:  Naohiro Ichino; Yuji Horiguchi; Hideo Imai; Keisuke Osakabe; Tohru Nishikawa; Yukiko Sugita; Hideko Utsugi; Yoko Togo; Tomoko Sawai; Yoshikazu Mizoguchi
Journal:  J Med Ultrason (2001)       Date:  2006-03       Impact factor: 1.314

Review 8.  Contrast-enhanced harmonic endoscopic ultrasound imaging: basic principles, present situation and future perspectives.

Authors:  María-Victoria Alvarez-Sánchez; Bertrand Napoléon
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 9.  Autoimmune pancreatitis: Multimodality non-invasive imaging diagnosis.

Authors:  Stefano Crosara; Mirko D'Onofrio; Riccardo De Robertis; Emanuele Demozzi; Stefano Canestrini; Giulia Zamboni; Roberto Pozzi Mucelli
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  Improved characterisation of solitary solid pancreatic tumours using contrast enhanced transabdominal ultrasound.

Authors:  C F Dietrich; B Braden; M Hocke; M Ott; A Ignee
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-19       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.